Alnylam Pharmaceuticals
Andrew Smith is currently serving as a Quality Control Analyst III at Alnylam Pharmaceuticals, where responsibilities include supporting Raw Materials, Microbiology, and Analytical teams through the performance of routine and non-routine analytical and microbiological assays. Previously, Andrew worked as an Associate II in Quality Control at Moderna, demonstrating proficiency in HPLC and other quality assurance methodologies, and as a QC Analyst at Amgen, utilizing compendial and internal methods to ensure material quality. Prior experience includes a Lab Technician role at Eurofins, focusing on pathogen testing in a GMP environment, and an Aquatics Specialist position at Petco, providing customer service and care for aquatic systems. Andrew holds a Bachelor of Arts in Marine Biology and Sustainability Studies from Roger Williams University, complemented by studies at the Bermuda Institute of Ocean Sciences.
This person is not in any teams
This person is not in any offices
Alnylam Pharmaceuticals
31 followers
Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market.